Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

DOI:10.1016/S1470-2045(23)00049-9
作者：Toni K Choueiri,?Masatoshi Eto,?Robert Motzer,?Ugo De Giorgi,?Tomas Buchler,?Naveen S Basappa,?María José Méndez-Vidal,?Sergei Tjulandin,?Se Hoon Park,?Bohuslav Melichar,?Thomas Hutson,?Carlos Alem
文献类型：期刊论文
补充材料：只需要正文